The 10 Wall Street analysts covering Cybin, Inc. hold a median 12-month price target of $46 — +269.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 42 of 100 as at 7 Sept 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Cybin, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (100): Smaller than most of the companies we track.
Value (9): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on HELP, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +269.1% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 20 Aug 2026 | TD Cowen | Maintains | Buy | $8.00 → $62 |
| 27 July 2026 | Wells Fargo | Initiates | Overweight | — |
| 27 July 2026 | Wells Fargo | Initiates | Overweight | $16 |
| 9 July 2026 | HC Wainwright & Co. | Maintains | Buy | $95 → $70 |
| 9 July 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 1 July 2026 | Canaccord Genuity | Maintains | Buy | — |
| 13 Apr 2026 | TD Cowen | Initiates | Buy | — |
| 2 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 3 Dec 2025 | Guggenheim | Maintains | Buy | — |
| 20 Nov 2025 | Canaccord Genuity | Maintains | Buy | — |
| 14 Nov 2025 | HC Wainwright & Co. | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. HELP appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 8 Sept 2026, Cybin, Inc. returned +97.6% against +19.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 87% of US stocks
Cheaper than 1% of US stocks
Cheaper than 84% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 15% of US stocks
Higher than 9% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Cybin, Inc. has a market value of $892.9M and an enterprise value of $1.2B.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$171.2M.
Free cash flow in the twelve months to 30 June 2026: −$142.3M.
Trailing P/E: −2.9×; forward P/E: −6.7× — the forward figure prices analyst consensus estimates, not reported earnings.
Cybin, Inc. employs 100 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Cybin, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Helus Pharma announced that CEO Michael Halstead will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference in New York on Friday, September 11, 2026 at 8:00 a.m. EDT.
Why it matters — The CEO's participation at a major global healthcare conference gives Helus Pharma visibility before an industry-focused audience.
Helus Pharma, a psychedelic drug developer with a pipeline spanning MDD and GAD, has two clinical-stage assets and a serotonergic discovery platform. The company is running a phase III trial for its oral psilocin candidate, HLP003, which could validate its clinical profile and reduce its valuation discount versus peers.
Why it matters — As a competitor with a similar psychedelic pipeline approaching a pivotal phase III readout, Helus Pharma's progress is relevant context for Cybin (HELP) watchers tracking the psychedelic development landscape.
Helus Pharma announced the appointments of Regina Donohue as Chief People Officer and Suresh Durgam, M.D., to its Scientific Advisory Board. Both are former executives of Intra-Cellular Therapies, bringing experience in organizational scale-up, CNS drug development, regulatory approvals, and commercialization.
Why it matters — For Cybin (HELP) watchers, the addition of executives with CNS drug development and commercialization experience could strengthen leadership and advisory expertise in the CNS space.
Helus Pharma reported its first quarter fiscal 2027 financial results and recent business highlights. The company also announced the appointment of Michael Halstead, former President of Intra-Cellular Therapies, as Chief Executive Officer to lead it through late-stage development and commercialization.
Why it matters — The appointment of an experienced CEO with commercialization background signals leadership focus on advancing Helus Pharma through late-stage development, which is relevant to the Cybin (HELP) investment page.
Helus Pharma has appointed Michael Halstead as its new Chief Executive Officer. Halstead previously served as President of Intra-Cellular Therapies, a company that was later acquired by Johnson & Johnson.
Why it matters — The appointment of a CEO with experience scaling a company that was acquired by a major pharmaceutical firm could signal strategic leadership changes at Helus Pharma.
The 10 Wall Street analysts covering Cybin, Inc. have a median 12-month price target of $46, with estimates ranging from $15 to $70. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 10 analysts covering Cybin, Inc., 10 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cybin, Inc. 42 out of 100 across roughly 4,600 US stocks as at 7 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 7 Sept 2026, Cybin, Inc. ranks 42 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (100 of 100).
No one can know that. What the data says: the median 12-month target from 10 analysts implies +269.1% from the last close, and Ticker Nerd's factor model ranks Cybin, Inc. 42 out of 100 as at 7 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Cybin, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HELP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $70 over the next 12 months.
Cybin, Inc. returned +97.6% over the 12 months to 8 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Cybin Inc. Common Stock represents Cybin Inc., a clinical-stage biopharmaceutical company focused on developing psychedelic-based therapeutics for mental health conditions.
The most recent item we track (GlobeNewsWire, 3 Sept 2026): "Helus Pharma to Participate at the 2026 Cantor Global Healthcare Conference in New York". Helus Pharma announced that CEO Michael Halstead will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference in New York on Friday, September 11, 2026 at 8:00 a.m. EDT.
Cybin Inc. Common Stock represents Cybin Inc., a clinical-stage biopharmaceutical company focused on developing psychedelic-based therapeutics for mental health conditions. The company is advancing a pipeline of investigational treatments designed to address psychiatric and neurological disorders, with work centered on proprietary compounds, drug delivery systems, and clinical research programs. Its current activities include late-stage and mid-stage development efforts for therapies targeting major depressive disorder and generalized anxiety disorder, alongside earlier-stage programs exploring additional neuropsychiatric uses. Cybin’s business is rooted in research and development, supported by partnerships and scientific collaborations that help advance its therapeutic platform. The company is headquartered in Toronto, Canada, and operates within the biotechnology and pharmaceutical research sectors, where it is known for its focus on next-generation mental health treatment options.
CEO Mr. Eric So L.L.B. · 100 employees · Canada · https://www.helus.com
